Gene Expression and Serum Protein Data for Irreversible Pulmonary Arterial Hypertension

A 2026 study by Genfa Xiao investigates the molecular switch from reversible to irreversible pulmonary arterial hypertension (PAH). The dataset includes transcriptomic analyses from public databases and serum protein levels from 80 clinical samples (40 CHD-PAH patients, 20 CHD patients, 20 healthy controls). It identifies lysosomal dysfunction and downregulated genes like Gnptab and M6pr as key factors in disease irreversibility.

Use Cases

• Identify gene expression biomarkers for irreversible PAH based on transcriptomic modules from WGCNA.
• Validate lysosomal enzyme trafficking dysfunction based on serum protein levels of CTSD, CTSB, and LGALS3.
• Explore the role of lysosomal hub genes (e.g., Ctsd, Ctsk, Lgals3) in disease progression based on pathway analyses.

Strengths

• Includes validation using 80 clinical serum samples from three patient groups.
• Identifies a set of eight lysosomal hub genes associated with disease irreversibility.
• Analysis is based on three independent transcriptomic datasets from the Gene Expression Omnibus.

Limitations

• The primary data file is a 2.8 MB DOCX document, which may not be a structured data format.
• Column-level documentation and sample data are unavailable, requiring manual inspection after download.
• Row count and specific data structure are unknown, limiting suitability assessment.

Provenance

Source

figshare, author Genfa Xiao.

Collection Method

Transcriptomic data obtained from the Gene Expression Omnibus; serum samples collected from patients and analyzed via ELISA.

Freshness

Last updated 2026-05-21 05:36:16.